ADMA Biologics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- 3rd quarter 2026 revenue was $141.1 million, up 5% year over year and 13% sequentially, including Ascendim revenue of $124.7 million, up 31% year over year and 21% sequentially.
- Bivegam revenue was $15.4 million, compared with $23.8 million a year ago and $19.4 million in the 2nd quarter, amid pricing and channel pressures.
- Gross profit was $99.9 million, and corporate gross margin was 71%, compared with 56% a year ago and 69% in the 2nd quarter.
- Adjusted EBITDA was $77.3 million, up 32% year over year and 25% sequentially; first 9 months adjusted EBITDA totaled $198.8 million.
- GAAP net income was $49.9 million, adjusted net income was $51.1 million, GAAP basic EPS was $0.22, and adjusted basic EPS was $0.23.
- Cash and cash equivalents totaled approximately $124.6 million at September 30th, 2026; cash from operations was $105 million year-to-date through September 30th, 2026.
- First 9 months of 2026 stock repurchases totaled $181.4 million, with 16.5 million shares repurchased, representing a 6.3% reduction in shares outstanding versus the end of 2025.
- Accounts receivable totaled $169.2 million, and DSOs were 110 days, above the target range of 90 to 105 days; management attributed the increase primarily to the timing of authorized distributor orders.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, and welcome to ADMA Biologics' third quarter 2026 financial results and business update conference call on Wednesday, November 4, 2026. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at the company's request and will be available on the company's website approximately two hours following the end of the call. At this time, I would like to introduce the company. Please go ahead. Welcome, everyone, and thank you for joining us this afternoon to discuss ADMA Biologics' financial results for the third quarter of 2026 and recent corporate updates.
I am joined today by Adam Grossman, our President and Chief Executive Officer, and Terry Kohler, our Chief Financial Officer and Treasurer. During today's call, Adam will provide some introductory comments and provide an update on corporate progress, and Terry will provide an overview of the company's third quarter 2026 financial results. Finally, Adam will then provide some brief summary remarks before opening the call up for questions. Earlier today, we issued a press release detailing our third quarter 2026 financial results, achievements, and recent corporate updates. The release is available on our website at www.admabiologics.com.
Before we begin our formal comments, I will remind you that we will be making forward-looking statements during today's call that represent the company's intentions, expectations, or beliefs concerning future events, which constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to factors, risks, and uncertainties such as those detailed in today's press release announcing this call and in our filings with the SEC, which may cause actual results to differ materially from the results expressed or implied by such statements. In addition, any forward-looking statements represent our views only as of the date of this call and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligations to update any such statements, except as required by the federal securities laws.
We refer you to the disclosures notice section in our earnings release we issued today and the risk factors section in our quarterly report on Form 10-Q for the quarter ended September 30, 2026, for a discussion of the important factors that could cause actual results to differ materially from these forward-looking statements. Please note, the discussion on today's call includes certain non-GAAP financial measures, including adjusted EBITDA, adjusted net income, and adjusted basic EPS. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP metric is available in our earnings release, which is available on our website at www.admabiologics.com. With that, I would now like to turn the call over to Adam Grossman. Adam? Thank you. Good afternoon, everyone, and thank you for joining us.
Our third quarter performance highlights two key items. First, we are seeing accelerating ASCENIV demand, and second, we are demonstrating our ability to translate commercial momentum into substantial earnings growth. Favorable product mix, yield-enhanced manufacturing, and disciplined execution are driving expanding profitability and meaningful earnings per share growth. We believe these two facts show the enduring strength of our business and ability to create value for stockholders. ASCENIV revenue reached $124.7 million, increasing 31% year-over-year and 21% sequentially. Total revenue grew 13% sequentially to $141.1 million, and corporate gross margin reached 71%. Year to date through September 30, 2026, the company has repurchased 16.5 million shares, representing approximately 6.3% of the shares outstanding at year-end 2025. We continue to execute against our previously reported target of $200 million or more in total share repurchases during 2026.
Terry will review the financial results and our capital allocation strategy in greater detail shortly. ASCENIV's momentum reflects underlying patient demand, supported by broader physician adoption, new patient starts, and increasing end-user utilization. Favorable distributor-reported pull-through continued into the fourth quarter, providing further confidence in the durability of ASCENIV's growth trajectory. We continue to experience strong momentum within the primary immunodeficiency patient population, where sustained growth in ASCENIV's utilization is contributing to an increasingly durable and expanding foundation of recurring patient demand. Importantly, we believe significant additional growth opportunities remain within secondary immunodeficiency patient populations, where recent growth has been moderate. However, we believe this population represents a potentially meaningful and largely untapped opportunity for ASCENIV.
As awareness of ASCENIV's differentiated clinical profile continues to expand among treating physicians, supported by our focused medical education and commercial initiatives, coupled with the growing body of scientific evidence, we are optimistic that adoption within these patient populations could accelerate in coming periods, providing a potential additional catalyst for sustained long-term product growth. We believe ASCENIV remains early in its penetration of later-line refractory and medically complex primary immunodeficiency patients. Its differentiated profile, expanding clinical evidence base support a significant long-term commercial opportunity. Turning to BIVIGAM, third quarter revenue was $15.4 million compared with $19.4 million in the second quarter, as standard IG pricing and competitive pressures persisted. While reported BIVIGAM revenue declined sequentially, underlying end-user utilization showed encouraging signs of stabilization entering into the fourth quarter. We continue to prioritize sustainable commercial participation rather than matching aggressive competitor rebating and discounting.
Our strategies reflect the distinct opportunities for each product, expanding ASCENIV's adoption through clinical engagement and real-world health outcomes evidence, while supporting BIVIGAM through disciplined contracting, manufacturing quality, and product-specific scientific differentiation. Our scientific evidence base continues to expand. At the upcoming ACAAI annual conference in November, we will be presenting real-world health outcomes data from 127 medically complex primary immunodeficiency patients, most of whom had previously received other immunoglobulin therapies. Comparing the 12 months before and after ASCENIV initiation, the analysis identified statistically significant reductions in infection-related hospitalizations, outpatient healthcare utilization, oral antibiotic use, and corticosteroid use. These findings add important evidence to physician and payer discussions regarding ASCENIV's role in treating appropriate patients. Separately, recently published peer-reviewed research examining thrombosis-related product attributes represents an important advancement in ADMA's scientific differentiation strategy, with particular relevance to BIVIGAM's competitive positioning in the U.S. standard immunoglobulin market.
As healthcare providers increasingly evaluate product quality, manufacturing consistency, and safety-related attributes alongside pricing and access, we believe these findings provide objective scientific evidence to support informed product evaluations and establish a more rigorous framework for assessing clotting-related activity and potential thrombosis risk across immunoglobulin products. We believe the totality of these data underscores the strength of ADMA's manufacturing capabilities, enhances our commercial education efforts, and provides an additional point of differentiation for BIVIGAM. We anticipate the scientific evidence will improve BIVIGAM's positioning in the competitive standard U.S. IG market, and this growing body of evidence will contribute to continued utilization stabilization and potential revenue growth for BIVIGAM in the coming periods. During the third quarter, we advanced SG-001, our investigational pneumococcal hyperimmune globulin candidate, through preclinical assay development and manufacturing readiness activities.
ADMAlytics, our proprietary AI platform, has helped accelerate SG-001's development by using computational modeling, artificial intelligence, and predictive analytics to forecast final titer values from limited experimental data. We believe this capital-efficient and data-driven approach can improve analytical efficiency and reduce laboratory testing requirements as we pursue SG-001's development using our established processes. Additionally, we are encouraged by the constructive FDA feedback the company received in late October on our SG-001 pre-IND meeting package, which we believe represents an important milestone for the pipeline program. Notably, we received constructive feedback from the FDA regarding the proposed clinical development strategy, including key elements of the planned clinical study. Based on the FDA's feedback, we intend to incorporate the recommendations into the final clinical protocol and advance preparations for an IND submission. The FDA also indicated that our proposed assay would be acceptable for product testing, subject to appropriate validation.
Collectively, we believe this regulatory feedback supports advancing this program forward with a potentially efficient development pathway that leverages ADMA's established manufacturing capabilities and clinical development experience as we move SG-001 towards a registrational clinical trial. We continue to believe SG-001 represents a potential $300 million-$500 million annual revenue opportunity, and we will continue to keep investors informed as the program progresses in the normal and ordinary course. We are reiterating our full-year revenue guidance of at least $530 million and increasing our minimum expectations for adjusted EBITDA and adjusted net income. We believe continued ASCENIV momentum, disciplined execution, and our financial position provide a strong foundation as we approach year-end. I'd like to thank our employees for their dedication to the patients which our products serve and continued execution across all functions of the business. Terry will now provide comments and dive into the financials. Terry? Thank you, Adam. I'll review our third quarter financial results, cash generation, and capital allocation, followed by our outlook for the remainder of 2026.
Third quarter revenue totaled $141.1 million, compared to $134.2 million a year ago and $124.4 million in the second quarter. Increasing 5% year-over-year and 13% sequentially. ASCENIV revenue of $124.7 million grew 31% year-over-year and 21% sequentially, and remained the primary driver of our performance. BIVIGAM revenue was $15.4 million, compared with $23.8 million one year ago, and $19.4 million in the second quarter. Pricing and channel pressures continued to weigh on reported revenue, although underlying end-user utilization showed encouraging signs of stabilization into the fourth quarter. Our guidance does not depend on the broad recovery of the standard IG market. Gross profit increased to $99.9 million from $75.6 million a year ago, and $86.3 million in the second quarter.
Gross margin rate 71%, compared to 56% a year ago, and 69% in the second quarter, representing approximately 1,450 basis points of year-over-year expansion. Favorable ASCENIV mix and yield-enhanced manufacturing were the principal drivers. Adjusted EBITDA was $77.3 million, increasing 32% year-over-year and 25% sequentially. For the first nine months, adjusted EBITDA totaled $198.8 million. Profitability growth exceeding revenue growth illustrates the operating leverage in our model. GAAP net income reached $49.9 million, increasing 37% year-over-year and 32% sequentially. Adjusted net income was $51.1 million, up approximately 31% both year-over-year and sequentially. GAAP basic EPS was $0.22, increasing 47% year-over-year and 29% sequentially. Adjusted basic EPS was $0.23, increasing 44% year-over-year and 35% sequentially. Strong earnings growth, together with ongoing share repurchases, is translating into meaningful growth in earnings per share.
Research and development expense was approximately $4.5 million, compared to $1.5 million a year ago, and $6 million in the second quarter, as we continued SG-001 development with lower sequential plasma collection activity. Selling, general, and administrative expense was approximately $26.6 million, essentially flat sequentially, and supporting commercial initiatives. As of September 30th, cash and cash equivalents totaled approximately $124.6 million. This liquidity provides flexibility to fund growth initiatives and return capital to stockholders. Net leverage continues to be under a half a turn. We continued repurchasing shares during the quarter. For the first nine months of 2026, total stock repurchases amounted to $181.4 million, with 16.5 million shares repurchased year-to-date through September, representing a reduction of 6.3% in ADMA shares outstanding versus the end of 2025. Our capital allocation approach balances per-share value creation with efficient investment in the core business.
Cash and cash equivalents increased approximately $36.9 million during the first nine months, despite significant share repurchases. Cash from operations was $105 million year-to-date through September 30th, 2026, an increase of over 600% versus the first nine months of 2025. Accounts receivable totaled $169.2 million at the end of the quarter, with DSOs increasing in the period to 110 days, which is modestly higher than our previously discussed DSO target of between 90 to 105 days. The driver of the DSO increase in the period was primarily the timing of orders from authorized distributors. We continue to collect all receivables with no history of bad debts, and will continue to work to drive DSOs back down into our target range over time. Turning to our updated full-year 2026 outlook, we continue to expect revenue of at least $530 million.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
7 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
